ArticleGene therapy1999

Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy.

A Hörster et al.PubMed ↗Publisher ↗

No numbers read from the abstract.